Goldman Sachs is in the spotlight as tech firms test IPO market

Malaysia News News

Goldman Sachs is in the spotlight as tech firms test IPO market
Malaysia Latest News,Malaysia Headlines
  • 📰 NBCNewYork
  • ⏱ Reading Time:
  • 13 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 63%

The drought in tech IPOs the past 18 months is about to break — and it’s a key moment for leading advisor Goldman Sachs.

initially to the roughly $55 billion that represents the top end of a target share price of $47 to $51.

Further, Arm is selling an unusually small slice of its overall stock, about 9%, which helps drive scarcity. That small public float means new investors will have fewer rights related to voting power and corporate governance, Trainer noted.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NBCNewYork /  🏆 270. in US

Malaysia Latest News, Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Goldman Sachs asset and wealth management executive to retire, as others join firmGoldman Sachs asset and wealth management executive to retire, as others join firmGoldman Sachs Group Inc. executive Laurence Stein is retiring after 27 years at the bank, according to an internal memo seen by MarketWatch. Stein was most...
Read more »

Goldman Sachs discloses short position in Philips after Dutch regulator review By ReutersGoldman Sachs discloses short position in Philips after Dutch regulator review By ReutersGoldman Sachs discloses short position in Philips after Dutch regulator review
Read more »

Hedge funds have bailed on the U.S. consumer in a big way, Goldman Sachs data findsHedge funds have bailed on the U.S. consumer in a big way, Goldman Sachs data findsHedge funds are betting that the U.S. consumer is in for a difficult ride.
Read more »

Goldman Sachs says this blood cancer treatment stock can gain 70% ahead of planned drug launchGoldman Sachs says this blood cancer treatment stock can gain 70% ahead of planned drug launchAnalyst Corinne Jenkins upgraded the firm to buy from neutral and maintained her price target of $4.
Read more »

Walgreens Boots, Goldman Sachs share gains lead Dow's nearly 100-point jumpWalgreens Boots, Goldman Sachs share gains lead Dow's nearly 100-point jumpThe Dow Jones Industrial Average is trading up Tuesday afternoon with shares of Walgreens Boots and Goldman Sachs delivering the strongest returns for the...
Read more »

Goldman Sachs, Walgreens Boots share gains contribute to Dow's 175-point jumpGoldman Sachs, Walgreens Boots share gains contribute to Dow's 175-point jumpShares of Goldman Sachs and Walgreens Boots are trading higher Tuesday afternoon, lifting the Dow Jones Industrial Average into positive territory. The Dow...
Read more »



Render Time: 2025-02-26 01:46:07